Never Run Out Of Buyers To Sell To.

Akrocell Biosciences is a startup biotech developing species-specific MSC-derived exosome therapeutics for companion animals, based on its proprietary HYCC™ (High Yield Combinatorial Culture) platform. HYCC™ enables consistent, large-scale production of species-specific mesenchymal stem cells and exosomes from a single donor — addressing a fundamental technical barrier that has long limited the veterinary regenerative medicine field. Our lead pipeline candidates are MSC-derived exosome therapeutics currently in preclinical development, targeting companion animal conditions with significant…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$1M to $5M
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.